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FMS-like tyrosine kinase 3 (FLT3) is a member of class III receptor tyrosine kinases and is expressed on hematopoietic stem/progenitor cells. FLT3 is also expressed in the vast majority of acute myeloid leukemia (AML) cells and the expression levels are more abundant than those of normal hematopoietic stem/progenitor cells. In addition, FLT3 mutations, including internal tandem duplication of the juxtamembrane domain
MV4-11
Src-Y419 Yes-Y426 Figure 1 The presence of FLT3-ITD is associated with the activation of p38 MAP kinase-MSK1 axis. (a) Whole cell lysates were prepared from FLT3-ITD expressing K562 sublines (F4-A-1 and F2-C-10), K562 and MV4-11, and hybridized with a human Phospho-Kinase array according to the manufacturer's instructions. The locations of some molecules are annotated. See Supplementary Table S1 for complete listing. (b) Signal intensities of the indicated molecules were quantified using Scion Image software (Scion Corporation, Frederick, MD, USA), and normalized to those of positive controls on the same membrane (setting at 1.0). The means ± s.d. (bars) of two independent experiments are shown. (c) Whole cell lysates were prepared from K562 sublines, parental K562 and MV4-11, and subjected to immunoblot analysis for the expression of phosphorylated ERK1/2, phosphorylated p38 MAP kinase, phosphorylated MSK1, and GAPDH (internal control). Total ERK1/2, p38 and MSK1 were almost equally expressed in all samples, and thus, omitted from the blot. Data shown are representative of multiple independent experiments. (d) Whole cell lysates were isolated from primary AML samples, and subjected to immunoblot analysis for the expression of phosphorylated MSK1, phosphorylated histone H3 and GAPDH (internal control). Total MSK1 and histone H3 were almost equally expressed in all samples, and thus, omitted from the blot. Reverse transcriptase-PCR (RT-PCR) analysis revealed that cases 1, 3 and 6 were positive for FLT3-ITD (data not shown).
of FLT 3 (FLT3-ITD) and point mutations in the activating loop, are observed in approximately 30% of patients with AML. Given the great success of imatinib mesylate in chronic myeloid leukemia (CML), FLT3 inhibitors are expected to improve the treatment outcome of AML patients with FLT3 mutations. The theoretical basis of the isobologram method has been previously described in detail. 4 The concentrations that produced 80% growth inhibition are expressed as 1.0 on the ordinate and abscissa. The envelope of additivity, surrounded by solid and broken lines, is constructed from dose-response curves of H89 and PKC412. When the data points fall within the area surrounded by the envelope of additivity, the combination is regarded as additive. When the data points fall to the left and right of the envelope, the drug combination is regarded as supra-additive (synergism) and antagonistic, respectively. Each data point represents the mean value of at least three independent experiments; the s.e.m. were o25% and were omitted. multiple stable transformants and verified the expression and phosphorylation of FLT3-ITD by immunoblotting. As shown in Supplementary Figure S1A , K562 sublines, F2-C-10 and F4-A-1, expressed FLT3-ITD at virtually identical levels to MV4-11. Importantly, FLT3-ITD was constitutively phosphorylated and thus was active in F2-C-10 and F4-A-1 cells, and constitutive phosphorylation of BCR-ABL was not impaired. Reflecting the dual expression of BCR-ABL and FLT3-ITD, these sublines responded to both imatinib and FLT3 inhibitors such as SU5416 and PKC412 (Supplementary Figure S1B) .
Using these cell lines, we attempted to identify the signaling pathways preferentially activated by FLT3-ITD and BCR-ABL. To accomplish this, we isolated protein samples from FLT3-ITD expressing K562 sublines along with parental K562 and MV4-11 cells, and subjected them to human Phospho-Kinase array, which allows simultaneous determination of the activation status of 46 different protein kinases and their downstream effectors (see Supplementary Materials and Methods for detailed procedures; Figure 1a shows a representative blot). This approach revealed that FLT3-ITD and BCR-ABL activated differential signaling pathways: the mitogen-activated protein (MAP) kinase pathway, especially p38-MSK1 (mitogen-and stress-activated kinase 1) axis by FLT3-ITD; and the JAK-STAT pathway, especially JAK2-STAT5 axis by BCR-ABL, although there was some overlap (Figure 1b) . It is noteworthy that FLT3-ITD expressing K562 sublines showed a pattern between parental cell lines MV4-11 and K562.
We then confirmed the results of Phospho-Kinase array with immunoblotting using antibodies different from those placed on the array. As shown in Figure 1c , MSK1 was exclusively phosphorylated in MV4-11 and FLT3-ITD expressing K562 sublines, and p38 MAP kinase was more abundantly phosphorylated in these cells than in K562 and mock-transfectants. Constitutive phosphorylation of MSK1 was also observed in another FLT3-ITD carrying cell line MOLM13 (data not shown). In contrast, no significant difference was observed in ERK1/2 phosphorylation in all cell lines examined. In addition, we examined MSK1 phosphorylation in primary AML samples from three FLT3-ITD-positive cases and three FLT3-ITD-negative cases including one case of CML-blastic crisis. As shown in Figure 1d , MSK1 phosphorylation was detected in all three FLT3-ITD-positive cases (cases 1, 3 and 6) and one FLT3-ITDnegative case (case 5), although there was a considerable case-to-case variation. MSK1 was not phosphorylated in other two FLT3-ITD-negative cases including the case with CMLblastic crisis (case 2). Constitutive activation of MSK1 was verified by monitoring the phosphorylation of histone H3 at serine-10, a canonical target site of MSK1.
3 H3-S10 phosphorylation was readily detected in all three FLT3-ITD-positive cases, although it was observed in case 4 independent of MSK1 activation.
Next, we analyzed whether MSK1 is indispensable for the maintenance of leukemic phenotype in AML cells carrying FLT3-ITD. To this end, we examined the effects of N-[2-pbromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H89), a potent inhibitor of MSK1, 3 on cell growth of FLT3-ITD expressing K562 sublines and parental cell lines. As shown in Figure 2a , H89 inhibited the growth of FLT3-ITD expressing K562 sublines (F4-A-1 and F2-C-10) and MV4-11 cells but not K562 and mock-transfectants M6-H-1 and M6-B-7. The growth suppression became apparent 4-5 days after treatment with H89, and was due to the induction of apoptosis rather than cell cycle arrest (Supplementary Figure S2) . The induction of apoptosis was accompanied by the reduced phosphorylation of H3-S10 (Figure 2b ). As H89 inhibits not only MSK1 but also other kinases such as protein kinase A and ROCK-II, we took advantage of small interfering RNA-mediated knockdown to confirm that MSK1 is crucial for FLT3-ITD function (lentiviral vectors encoding short hairpin RNAs against MSK1 and scrambled controls were obtained from Open Biosystems, Huntsville, AL, USA). The numbers of apoptotic cells significantly increased along with the downregulation of MSK1 expression in MV4-11 (Figure 2c ) and MOLM13 cells (data not shown) but not in K562 cells (data not shown). These results suggest that MSK1 is a critical downstream effecter of FLT3-ITDmediated anti-apoptotic signal in AML cells.
Finally, we evaluated the cytotoxic interactions of H89 and PKC412 in MV4-11 cells using the isobologram of Steel and Peckham. 4 As anticipated, the two agents showed synergistic effects on MV4-11 and MOLM13 cells (Figure 2d and data not shown). In addition, H89 was also synergistic with another FLT inhibitor SU5416 (data not shown), suggesting that H89 and FLT3 inhibitors produce better effects in combination.
MSK1 was originally identified as a serine/threonine kinase activated by ERK1/2 and p38 in response to mitogenic stimuli as well as stress signals. Kim et al. 5 reported that H89 suppressed the transformation of murine epidermal cells by epidermal growth factor and 12-O-tetradecanoyl-phorbol-13-acetate, suggesting that MSK-1 is indispensable for carcinogenesis. Our findings suggest that the p38 MAP kinase-MSK1 axis also contributes to FLT3-ITD-mediated leukemogenesis. This is consistent with the previous observation that p38 is involved in cytokine-induced proliferation of an AML cell line. 6 In contrast, p38-MSK1 was not activated in CML-derived K562 cell line. Recently, it has been reported that the activation of p38 is essential for the effects of BCR-ABL inhibitors, implying that BCR-ABL promotes leukemogenesis via the suppression of the p38 MAP kinase pathway. 7, 8 Taken together, these findings underscore the difference in the mechanisms of leukemogenesis by FLT3-ITD and BCR-ABL. Inhibition of the p38-MSK1 pathway might be an alternative for treatment of AML carrying FLT3 mutations.
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The authors declare no conflict of interest. Juvenile myelomonocytic leukemia (JMML) is a rare form of myeloproliferative disorder, which is characterized by excessive myelomonocytic proliferation. 1 Gene mutations on RAS signaling pathways are a hallmark of JMML and are thought to be central to the pathogenesis of JMML. Mutations of NF1, NRAS, KRAS and PTPN11 genes are found in approximately 70% of JMML patients, and are implicated in the aberrant RAS signaling.
1 On the other hand, the remaining approximately 30% of JMML patients have no known mutations.
In this regard, recent reports of somatic mutations of the CBL proto-oncogene in myeloid neoplasms are intriguing, because these CBL mutations were shown to result in aberrant tyrosine kinase signaling, which would lead also to activation of RAS signaling pathways.
2-4 We 2 and others 3,4 reported that CBL mutations occurred in a variety of myeloid neoplasms in adults, especially in chronic myelomonocytic leukemia, [2] [3] [4] which prompted us to search for possible CBL mutations in JMML cases as well as pediatric myelodysplastic syndrome (MDS) patients.
In total, 40 primary JMML and 24 pediatric MDS specimens were examined for CBL mutations. The median age at diagnosis of JMML was 1 year and 10 months (range, 2 months to 8 years and 4 months), and the study included 25 male and 15 female patients. MDS patients included 9 patients with refractory anemia, 14 with refractory anemia with excess of blasts and 1 with secondary MDS. As CBL mutations thus far reported almost exclusively involved exons 7-9 that encode linker/RING finger domains, 2-4 we confined our analysis to these exons using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Branchburg, NJ, USA). Of the 40 JMML samples, 24 were also analyzed using Affymetrix GeneChip 250K NspI (Santa Clara, CA, USA).
5 Genome-wide detection of copy number abnormalities or allelic imbalances was performed using CNAG/ AsCNAR software (http://www.genome.umin.jp), 5 which enabled sensitive detection of copy number neutral loss of heterozygosity (or acquired uniparental disomy (aUPD)).
5
Mutations of RAS and PTPN11 were also examined as previously reported. 6 The study adhered to the principles of the Helsinki Declaration, and was conducted under the regulations enacted by the Ethics Board of Gunma Children's Medical Center.
CBL mutations were identified in 3 out of 40 JMML samples (7.5%), which were located in the linker sequence (Y371H in UPN1) or in the RING finger domain (C416Y in UPN18 and C419R in UPN38). The origin of the mutations has not been determined owing to the lack of appropriate normal tissues. All 3 CBL-mutated cases accompanied 11q-aUPD, whereas heterozygosity of 11q was preserved in the remaining 21 patients with wild-type CBL, recapitulating a strong association of CBL mutations with 11q-aUPD as previously described.
2 In UPN18, the chromatogram exclusively showed a mutated sequence, indicating that the mutation (C416Y) was homozygous. In the remaining patients, chromatograms were apparently heterozygous (Figure 1) . Nevertheless, this did not necessarily exclude the possibility of homozygous mutations in the aUPD-positive cells, which were found in a small fraction within these tumor samples, as estimated from allele-specific copy numbers.
Recently, Loh et al. 7 have reported on CBL mutations in 27 (17%) of 159 JMML patients, which were exclusive with regard to RAS/PTPN11 mutations. They also showed that Y371H mutations represented nearly 50% of all CBL mutations in JMML, 7 which were also found in a patient in our series. Mutations of NRAS, KRAS and PTPN11 genes were found in 18, 10 and 34% of patients in our series, respectively, which did not co-exist with three CBL mutations (Table 1) . In our study, no CBL mutations were found in 24 pediatric MDS patients. Combining both studies, the prevalence of CBL mutations is expected to be significantly lower in pediatric MDS patients than in JMML patients (0/24 vs 30/199; P ¼ 0.025), although the number of patients is still small. CBL is a negative modulator of tyrosine kinase signaling and, as such, was demonstrated to act functionally and genetically as a tumor suppressor. On the other hand, CBL mutants in myeloid neoplasms have clear oncogenic properties, because they strongly transform fibroblasts. These CBL mutants inhibit the E3 ubiquitin ligase activity of both wild-type CBL and CBL-B, leading to prolonged tyrosine kinase activity after cytokine stimulation and hypersensitive proliferative responses of hematopoietic progenitors to a wide variety of cytokines. 8 We have recently shown that the biological consequence of CBL mutations is prolonged activation of tyrosine kinases after cytokine/growth factor stimulations, which is further augmented under the CBL-null background as caused by aUPD.
2 Thus, CBL mutations associated with 11q-aUPD in JMML could provide a feasible explanation to the hypersensitivity to GM-CSF, which is
